Article(id=1326652740199101220, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652739800642340, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.05.003, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1731772800000, receivedDateStr=2024-11-17, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228261279, onlineDateStr=2026-11-09, pubDate=1746806400000, pubDateStr=2025-05-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228261279, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228261279, creator=13701087609, updateTime=1794228261279, updator=13701087609, issue=Issue{id=1326652739800642340, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='5', pageStart='429', pageEnd='528', issueExtLink='null', onlineDate='null', pubDate='1746806400000', pubDateStr='2025-05-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228261184, creator='13701087609', updateTime=1794273040769, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326840559311893443, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652739800642340, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326840559311893444, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652739800642340, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=439, endPage=445, ext={EN=ArticleExt(id=1326652740463342373, articleId=1326652740199101220, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress of biologics in the treatment of atopic dermatitis, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Atopic dermatitis (AD) is a common chronic inflammatory skin disease that seriously affects the quality of life of patients. Traditional treatments such as topical steroids and immunosuppressants have limited efficacy in some patients and are accompanied by adverse reactions. In recent years, biologics have provided new treatment options for patients with moderate to severe AD by targeting key inflammatory factors. Dupilumab, as the first approved biologic, significantly improved patients' skin symptoms and pruritus. Subsequently, drugs such as tralokinumab, lebrikizumab, and nemolizumab further expanded the options for targeted therapy. Biologics have shown promising prospects in improving the treatment outcomes of patients with moderate to severe AD, and are expected to further improve efficacy and affordability through personalized medicine, optimized dosing strategies, and cost control. This article reviewed the targets, mechanisms of action, and clinical research progress of major biological agents, in order to provide reference for the clinical treatment of AD patients.

, authors=Zhuo ZHANG1, Cheng QIN1, Fang WANG1, Xuesong YANG2, Jianzhou YE2, *, authorsList=Zhuo ZHANG, Cheng QIN, Fang WANG, Xuesong YANG, Jianzhou YE, authorCompany=null, correspAuthors=Jianzhou YE, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326652740975047463, articleId=1326652740199101220, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=生物制剂在特应性皮炎治疗中的研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

特应性皮炎(atopic dermatitis,AD)是一种常见的慢性炎症性皮肤病,严重影响患者生活质量。传统治疗如局部类固醇及免疫抑制剂在部分患者中疗效有限,且伴有不良反应。近年来,生物制剂通过靶向关键炎症因子,为中重度AD患者提供全新的治疗选择。度普利尤单抗作为首个获批的生物制剂,可改善患者的皮肤症状及瘙痒感,随后曲罗芦单抗、来瑞组单抗及奈莫利珠单抗等药物进一步丰富了靶向治疗的选择。生物制剂在提升中重度AD患者的治疗效果方面展现出良好的应用前景,并有望通过个性化医学、优化给药策略及成本控制进一步提升疗效和可负担性。该文就主要生物制剂的作用靶点、作用机制及临床研究进展作综述,以期为AD患者的临床治疗提供参考。

, authors=张卓1, 秦成1, 王芳1, 杨雪松2, 叶建州2, *, authorsList=张卓, 秦成, 王芳, 杨雪松, 叶建州, authorCompany=null, correspAuthors=叶建州, authorNote=

张卓,研究方向:特应性皮炎的防治。

, correspAuthorsNote=
叶建州,主任医师,研究方向:特应性皮炎的防治。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=N8Oh35glhpPLKh74NdzFiA==, magXml=Pl8UXU60e98NKGAV+5xPKA==, pdfUrl=null, pdf=eyOQETAyu0vVOnoRV9fI5g==, pdfFileSize=917186, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=j+9CtzTzz1uzeGe6n3He0A==, mapNumber=null, fund=null)}, authors=[Author(id=1326652742937981743, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652743026062129, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652742937981743, language=EN, stringName=Zhuo ZHANG, firstName=Zhuo, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652743093170994, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652742937981743, language=CN, stringName=张卓, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.云南中医药大学第一临床医学院,云南 昆明 650500, bio={"content":"

张卓,研究方向:特应性皮炎的防治。

"}, bioImg=null, bioContent=

张卓,研究方向:特应性皮炎的防治。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652742694712104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, xref=1., ext=[AuthorCompanyExt(id=1326652742703100713, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China), AuthorCompanyExt(id=1326652742711489322, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.云南中医药大学第一临床医学院,云南 昆明 650500)])]), Author(id=1326652743160279860, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652743256748854, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743160279860, language=EN, stringName=Cheng QIN, firstName=Cheng, middleName=null, lastName=QIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652743315469111, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743160279860, language=CN, stringName=秦成, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.云南中医药大学第一临床医学院,云南 昆明 650500, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652742694712104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, xref=1., ext=[AuthorCompanyExt(id=1326652742703100713, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China), AuthorCompanyExt(id=1326652742711489322, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.云南中医药大学第一临床医学院,云南 昆明 650500)])]), Author(id=1326652743369995065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652743441298235, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743369995065, language=EN, stringName=Fang WANG, firstName=Fang, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652743504212796, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743369995065, language=CN, stringName=王芳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.云南中医药大学第一临床医学院,云南 昆明 650500, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652742694712104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, xref=1., ext=[AuthorCompanyExt(id=1326652742703100713, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China), AuthorCompanyExt(id=1326652742711489322, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.云南中医药大学第一临床医学院,云南 昆明 650500)])]), Author(id=1326652743567127358, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652743655207744, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743567127358, language=EN, stringName=Xuesong YANG, firstName=Xuesong, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Dermatology, The First Affiliated Hospital, Yunnan University of Traditional Chinese Medicine, Kunming 650500,Yunnan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652743713928001, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743567127358, language=CN, stringName=杨雪松, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.云南中医药大学第一附属医院皮肤科,云南 昆明 650500, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652742816346923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, xref=2., ext=[AuthorCompanyExt(id=1326652742841512748, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742816346923, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Dermatology, The First Affiliated Hospital, Yunnan University of Traditional Chinese Medicine, Kunming 650500,Yunnan Province, China), AuthorCompanyExt(id=1326652742875067181, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742816346923, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.云南中医药大学第一附属医院皮肤科,云南 昆明 650500)])]), Author(id=1326652743768453955, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652743843951429, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743768453955, language=EN, stringName=Jianzhou YE, firstName=Jianzhou, middleName=null, lastName=YE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Dermatology, The First Affiliated Hospital, Yunnan University of Traditional Chinese Medicine, Kunming 650500,Yunnan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652743902671686, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743768453955, language=CN, stringName=叶建州, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.云南中医药大学第一附属医院皮肤科,云南 昆明 650500, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652742816346923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, xref=2., ext=[AuthorCompanyExt(id=1326652742841512748, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742816346923, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Dermatology, The First Affiliated Hospital, Yunnan University of Traditional Chinese Medicine, Kunming 650500,Yunnan Province, China), AuthorCompanyExt(id=1326652742875067181, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742816346923, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.云南中医药大学第一附属医院皮肤科,云南 昆明 650500)])])], keywords=[Keyword(id=1326652743982363463, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, language=EN, orderNo=1, keyword=atopic dermatitis), Keyword(id=1326652744049472328, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, language=EN, orderNo=2, keyword=biological agents), Keyword(id=1326652744124969801, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, language=EN, orderNo=3, keyword=biological function), Keyword(id=1326652744196272970, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, language=CN, orderNo=1, keyword=特应性皮炎), Keyword(id=1326652744250798923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, language=CN, orderNo=2, keyword=生物制剂), Keyword(id=1326652744309519180, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, language=CN, orderNo=3, keyword=生物学功能)], refs=[Reference(id=1326652744506651470, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=FRAZIER W, BHARDWAJ N. Atopic dermatitis: diagnosis and treatment[J]. Am Fam Physician, 2020, 101(10): 590-598., articleTitle=null, refAbstract=null), Reference(id=1326652744561177423, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=SROKA-TOMASZEWSKA J, TRZECIAK M. Molecular mechanisms of atopic dermatitis pathogenesis[J]. Int J Mol Sci, 2021, 22(8): 4130., articleTitle=null, refAbstract=null), Reference(id=1326652744628286288, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=SCHULER C F, BILLI AC, MAVERAKIS E, et al. Novel insights into atopic dermatitis[J]. J Allergy Clin Immunol,2023, 151(5): 1145-1154., articleTitle=null, refAbstract=null), Reference(id=1326652744695395153, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=GATMAITAN JG, LEE JH. Challenges and future trends in atopic dermatitis[J]. Int J Mol Sci, 2023, 24(14): 11380., articleTitle=null, refAbstract=null), Reference(id=1326652744766698322, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=EICHENFIELD LF, STRIPLING S, FUNG S, et al. Recent developments and advances in atopic dermatitis: A focus on epidemiology, pathophysiology, and treatment in the pediatric setting[J]. Pediatric Drugs, 2022, 24(4): 293-305., articleTitle=null, refAbstract=null), Reference(id=1326652744825418579, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=BOCQUEL S, SORIA A, RAISON-PEYRON N, et al.Impact of dupilumab on patch test results and allergic contact dermatitis: a prospective multicenter study[J]. J Am Acad Dermatol, 2024, 90(3): 512-520., articleTitle=null, refAbstract=null), Reference(id=1326652744909304660, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=BANGERT C, RINDLER K, KRAUSGRUBER T, et al.Persistence of mature dendritic cells, Th2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Rα blockade[J]. Sci Immunol, 2021, 6(55): eabe2749., articleTitle=null, refAbstract=null), Reference(id=1326652744972219221, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=TOMINAGA M, TAKAMORI K. Peripheral itch sensitization in atopic dermatitis[J]. Allergol Int, 2022, 71(3): 265-277., articleTitle=null, refAbstract=null), Reference(id=1326652745035133782, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=FURUE M, ULZII D, VU YH, et al. Pathogenesis of atopic dermatitis: current paradigm[J]. Iran J Immunol, 2019,16(2): 97-107., articleTitle=null, refAbstract=null), Reference(id=1326652745093854039, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=RENERT-YUVAL Y, THYSSEN JP, BISSONNETTE R, et al. Biomarkers in atopic dermatitis - a review on behalf of the International Eczema Council[J]. J Allergy Clin Immunol,2021, 147(4): 1174-1190., articleTitle=null, refAbstract=null), Reference(id=1326652745152574296, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=LUGOVIC-MIHIC L, MESTROVIC-STEFEKOV J,POTOCNJAK I, et al. Atopic dermatitis: disease features,therapeutic options, and a multidisciplinary approach[J].Life(Basel), 2023, 13(6): 1419., articleTitle=null, refAbstract=null), Reference(id=1326652745215488857, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=YANG G, SEOK JK, KANG HC, et al. Skin barrier abnormalities and immune dysfunction in atopic dermatitis[J]. Int J Mol Sci, 2020, 21(8): 2867., articleTitle=null, refAbstract=null), Reference(id=1326652746880627546, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=BECK LA, CORK MJ, AMAGAI M, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis[J]. JID Innov, 2022, 2(5): 100131., articleTitle=null, refAbstract=null), Reference(id=1326652746968707931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=KIM J, KIM BE, LEUNG DYM. Pathophysiology of atopic dermatitis: clinical implications[J]. Allergy Asthma Proc,2019, 40(2): 84-92., articleTitle=null, refAbstract=null), Reference(id=1326652747035816796, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=KIM Y, LIM K. Skin barrier dysfunction and filaggrin[J].Arch Pharm Res, 2021, 44(1): 36-48., articleTitle=null, refAbstract=null), Reference(id=1326652747144868701, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=RENERT-YUVAL Y, GUTTMAN-YASSKY E. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines[J]. Ann Allergy Asthma Immunol, 2020, 124(1):28-35., articleTitle=null, refAbstract=null), Reference(id=1326652747207783262, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=BRIDGEWOOD C, NEWTON D, BRAGAZZI N, et al.Unexpected connections of the IL-23/IL-17 and IL-4/IL-13 cytokine axes in inflammatory arthritis and enthesitis[J].Semin Immunol, 2021, 58: 101520., articleTitle=null, refAbstract=null), Reference(id=1326652747283280735, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=BRIDGEWOOD C, SHARIF K, FREESTON J, et al.Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy[J]. Rheumatology(Oxford), 2021, 60(5):2461-2466., articleTitle=null, refAbstract=null), Reference(id=1326652747371361120, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=SCIBIOREK M, MTHEMBU N, MANGALI S, et al. IL-4Rα signalling in B cells and T cells play differential roles in acute and chronic atopic dermatitis[J]. Sci Rep, 2023, 13(1): 144., articleTitle=null, refAbstract=null), Reference(id=1326652747472024417, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=JOHNSON MC, BOWERS NL, STROWD LC. Concurrent atopic dermatitis and psoriasis vulgaris: implications for targeted biologic therapy[J]. Cutis, 2022, 109(2): 110-112., articleTitle=null, refAbstract=null), Reference(id=1326652747585270626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=DUBIN C, DEL DUCA E, GUTTMAN-YASSKY E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis[J]. Expert Rev Clin Immunol, 2021, 17(8): 835-852., articleTitle=null, refAbstract=null), Reference(id=1326652747681739619, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=HASHIMOTO T, YOKOZEKI H, KARASUYAMA H, et al.IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin[J]. J Allergy Clin Immunol, 2023, 151(3): 737-746., articleTitle=null, refAbstract=null), Reference(id=1326652747744654180, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=KEAM SJ. Nemolizumab: first approval[J]. Drugs, 2022,82(10): 1143-1150., articleTitle=null, refAbstract=null), Reference(id=1326652747815957349, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=SERRA-BALDRICH E, SANTAMARIA-BABI L F,FRANCISCO SILVESTRE J. Nemolizumab: An innovative biologic treatment to control interleukin 31, a key mediator in atopic dermatitis and prurigo nodularis[J]. Actas Dermosifiliogr , 2022, 113(7): 674-684., articleTitle=null, refAbstract=null), Reference(id=1326652747878871910, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=FURUE M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis[J]. Int J Mol Sci, 2020,21(15): 5382., articleTitle=null, refAbstract=null), Reference(id=1326652747975340903, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=BOROWCZYK J, SHUTOVA M, BREMBILLA NC,et al. IL-25(IL-17E) in epithelial immunology and pathophysiology[J]. J Allergy Clin Immunol, 2021, 148(1):40-52., articleTitle=null, refAbstract=null), Reference(id=1326652748050838376, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=LIU TM, LI S, YING SN, et al. The IL-23/IL-17 pathway in inflammatory skin diseases: from bench to bedside[J]. Front Immunol, 2020, 11: 594735., articleTitle=null, refAbstract=null), Reference(id=1326652748143113065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=REICH K, THYSSEN JP, BLAUVELT A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised,double-blind, multicentre phase 3 trial[J]. Lancet, 2022,400(10348): 273-282., articleTitle=null, refAbstract=null), Reference(id=1326652748222804842, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=GUTTMAN-YASSKY E, BISSONNETTE R, UNGAR B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis[J].J Allergy Clin Immunol, 2019, 143(1): 155-172., articleTitle=null, refAbstract=null), Reference(id=1326652748319273835, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=SILVERBERG JI, YOSIPOVITCH G, SIMPSON EL,et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS[J]. J Am Acad Dermatol, 2020, 82(6): 1328-1336., articleTitle=null, refAbstract=null), Reference(id=1326652748407354220, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=BLAUVELT A, DE BRUIN-WELLER M, GOODERHAM M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids(LIBERTY AD CHRONOS): a 1-year,randomised, double-blinded, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10086): 2287-2303., articleTitle=null, refAbstract=null), Reference(id=1326652748470268781, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=KOSKERIDIS F, EVANGELOU E, NTZANI EE, et al.Treatment with dupilumab in patients with atopic dermatitis:systematic review and meta-analysis[J]. J Cutan Med Surg,2022, 26(6): 613-621., articleTitle=null, refAbstract=null), Reference(id=1326652748541571950, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=BLAUVELT A, GUTTMAN-YASSKY E, PALLER AS, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: Results through week 52 from a phase Ⅲ open-label extension trial(LIBERTY AD PED-OLE)[J]. Am J Clin Dermatol, 2022, 23(3): 365-383., articleTitle=null, refAbstract=null), Reference(id=1326652748608680815, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=MULLER S, MAINTZ L, BIEBER T. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs[J]. Allergy, 2024, 79(6): 1501-1515., articleTitle=null, refAbstract=null), Reference(id=1326652748675789680, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=WOLLENBERG A, BLAUVELT A, GUTTMAN-YASSKY E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized,double-blind, multicentre, placebo-controlled phase Ⅲtrials(ECZTRA 1 and ECZTRA 2)[J]. Br J Dermatol, 2021,184(3): 437-449., articleTitle=null, refAbstract=null), Reference(id=1326652748742898545, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=PEREYRA-RODRIGUEZ JJ, HERRANZ P, RUIZ-VILLAVERDE R, et al. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results[J]. Clin Exp Dermatol, 2023,48(9): 991-997., articleTitle=null, refAbstract=null), Reference(id=1326652748810007410, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=DE GREEF A, BAECK M. Tralokinumab-induced injection-site reactions[J]. Contact Dermatitis, 2024, 91(6): 521-522., articleTitle=null, refAbstract=null), Reference(id=1326652748877116275, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=SILVERBERG JI, THYSSEN JP, FAHRBACH K, et al.Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis[J]. J Eur Acad Dermatol Venereol, 2021, 35(9): 1797-1810., articleTitle=null, refAbstract=null), Reference(id=1326652748940030836, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=OKRAGLY AJ, RYUZOJI A, WULUR I, et al. Binding,neutralization and internalization of the interleukin-13 antibody, lebrikizumab[J]. Dermatol Ther, 2023, 13(7):1535-1547., articleTitle=null, refAbstract=null), Reference(id=1326652749007139701, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=SIMPSON EL, DE BRUIN-WELLER M, HONG HC, et al.Lebrikizumab provides rapid clinical responses across all eczema area and severity index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis[J]. Dermatol Ther(Heidelb), 2024, 14(5): 1145-1160., articleTitle=null, refAbstract=null), Reference(id=1326652749078442870, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=BUTALA S, CASTELO-SOCCIO L, SESHADRI R, et al.Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations[J]. J Allergy Clin Immunol Pract, 2023, 11(5): 1361-1373., articleTitle=null, refAbstract=null), Reference(id=1326652749132968823, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=RATCHATASWAN T, BANZON TM, THYSSEN JP, et al.Biologics for treatment of atopic dermatitis: current status and future prospect[J]. J Allergy Clin Immunol Pract, 2021,9(3): 1053-1065., articleTitle=null, refAbstract=null), Reference(id=1326652749200077688, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=YANG N, CHEN ZY, ZHANG XL, et al. Novel targeted biological agents for the treatment of atopic dermatitis[J].Bio Drugs, 2021, 35(4): 401-415., articleTitle=null, refAbstract=null), Reference(id=1326652749267186553, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=LABIB A, VANDER DOES A, YOSIPOVITCH G.Nemolizumab for atopic dermatitis[J]. Drugs Today(Barc),2022, 58(4): 159-173., articleTitle=null, refAbstract=null), Reference(id=1326652749334295418, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=KWATRA SG, YOSIPOVITCH G, LEGAT FJ, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis[J]. N Engl J Med, 2023, 389(17): 1579-1589., articleTitle=null, refAbstract=null), Reference(id=1326652749397209979, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=KABASHIMA K, MATSUMURA T, KOMAZAKI H, et al.Trial of nemolizumab and topical agents for atopic dermatitis with pruritus[J]. N Engl J Med, 2020, 383(2): 141-150., articleTitle=null, refAbstract=null), Reference(id=1326652749476901756, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=NILFOROUSHZADEH MA, HEIDARI N, GHANE Y, et al. A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis[J]. Inflammopharmacology,2024, 32(2): 991-1003., articleTitle=null, refAbstract=null), Reference(id=1326652749573370749, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=FURUE M, FURUE M. Interleukin-31 and pruritic skin[J]. J Clin Med, 2021, 10(9): 1906., articleTitle=null, refAbstract=null), Reference(id=1326652749665645438, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=FUKUMOTO T, TANAKA R, TANAKA R, et al. Primary localized cutaneous amyloidosis associated with atopic dermatitis treated successfully with nemolizumab[J]. J Eur Acad Dermatol Venereol, 2024, 38(11): e989-e992., articleTitle=null, refAbstract=null)], funds=[Fund(id=1326652744410182477, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, awardId=82260940, language=CN, fundingSource=国家自然科学基金项目(82260940), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1326652742694712104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, xref=1., ext=[AuthorCompanyExt(id=1326652742703100713, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China), AuthorCompanyExt(id=1326652742711489322, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.云南中医药大学第一临床医学院,云南 昆明 650500)]), AuthorCompany(id=1326652742816346923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, xref=2., ext=[AuthorCompanyExt(id=1326652742841512748, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742816346923, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Dermatology, The First Affiliated Hospital, Yunnan University of Traditional Chinese Medicine, Kunming 650500,Yunnan Province, China), AuthorCompanyExt(id=1326652742875067181, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742816346923, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.云南中医药大学第一附属医院皮肤科,云南 昆明 650500)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.05.003, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.05.003, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.05.003, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.05.003, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1746806400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
生物制剂在特应性皮炎治疗中的研究进展
张卓 1 , 秦成 1 , 王芳 1 , 杨雪松 2 , 叶建州 2, *
世界临床药物 | 医药专论 2025,46(5): 439-445
收起
收藏切换
世界临床药物 |医药专论 2025 , 46 (5) : 439 -445
生物制剂在特应性皮炎治疗中的研究进展
全屏
[Author(id=1326652742937981743, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652743026062129, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652742937981743, language=EN, stringName=Zhuo ZHANG, firstName=Zhuo, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652743093170994, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652742937981743, language=CN, stringName=张卓, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.云南中医药大学第一临床医学院,云南 昆明 650500, bio={"content":"

张卓,研究方向:特应性皮炎的防治。

"}, bioImg=null, bioContent=

张卓,研究方向:特应性皮炎的防治。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652742694712104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, xref=1., ext=[AuthorCompanyExt(id=1326652742703100713, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China), AuthorCompanyExt(id=1326652742711489322, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.云南中医药大学第一临床医学院,云南 昆明 650500)])]), Author(id=1326652743160279860, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652743256748854, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743160279860, language=EN, stringName=Cheng QIN, firstName=Cheng, middleName=null, lastName=QIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652743315469111, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743160279860, language=CN, stringName=秦成, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.云南中医药大学第一临床医学院,云南 昆明 650500, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652742694712104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, xref=1., ext=[AuthorCompanyExt(id=1326652742703100713, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China), AuthorCompanyExt(id=1326652742711489322, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.云南中医药大学第一临床医学院,云南 昆明 650500)])]), Author(id=1326652743369995065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652743441298235, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743369995065, language=EN, stringName=Fang WANG, firstName=Fang, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652743504212796, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743369995065, language=CN, stringName=王芳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.云南中医药大学第一临床医学院,云南 昆明 650500, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652742694712104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, xref=1., ext=[AuthorCompanyExt(id=1326652742703100713, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China), AuthorCompanyExt(id=1326652742711489322, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742694712104, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.云南中医药大学第一临床医学院,云南 昆明 650500)])]), Author(id=1326652743567127358, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652743655207744, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743567127358, language=EN, stringName=Xuesong YANG, firstName=Xuesong, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Dermatology, The First Affiliated Hospital, Yunnan University of Traditional Chinese Medicine, Kunming 650500,Yunnan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652743713928001, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743567127358, language=CN, stringName=杨雪松, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.云南中医药大学第一附属医院皮肤科,云南 昆明 650500, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652742816346923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, xref=2., ext=[AuthorCompanyExt(id=1326652742841512748, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742816346923, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Dermatology, The First Affiliated Hospital, Yunnan University of Traditional Chinese Medicine, Kunming 650500,Yunnan Province, China), AuthorCompanyExt(id=1326652742875067181, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742816346923, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.云南中医药大学第一附属医院皮肤科,云南 昆明 650500)])]), Author(id=1326652743768453955, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652743843951429, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743768453955, language=EN, stringName=Jianzhou YE, firstName=Jianzhou, middleName=null, lastName=YE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Dermatology, The First Affiliated Hospital, Yunnan University of Traditional Chinese Medicine, Kunming 650500,Yunnan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652743902671686, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, authorId=1326652743768453955, language=CN, stringName=叶建州, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.云南中医药大学第一附属医院皮肤科,云南 昆明 650500, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652742816346923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, xref=2., ext=[AuthorCompanyExt(id=1326652742841512748, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742816346923, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Dermatology, The First Affiliated Hospital, Yunnan University of Traditional Chinese Medicine, Kunming 650500,Yunnan Province, China), AuthorCompanyExt(id=1326652742875067181, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652740199101220, companyId=1326652742816346923, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.云南中医药大学第一附属医院皮肤科,云南 昆明 650500)])])]
张卓1, 秦成1, 王芳1, 杨雪松2, 叶建州2, *
作者信息
  • 1.云南中医药大学第一临床医学院,云南 昆明 650500
  • 2.云南中医药大学第一附属医院皮肤科,云南 昆明 650500
通讯作者:
叶建州,主任医师,研究方向:特应性皮炎的防治。
作者简介:

张卓,研究方向:特应性皮炎的防治。

Research progress of biologics in the treatment of atopic dermatitis
Zhuo ZHANG1, Cheng QIN1, Fang WANG1, Xuesong YANG2, Jianzhou YE2, *
Affiliations
  • 1.The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming 650500, Yunnan Province, China
  • 2.Department of Dermatology, The First Affiliated Hospital, Yunnan University of Traditional Chinese Medicine, Kunming 650500,Yunnan Province, China
出版时间: 2025-05-10 doi: 10.13683/j.wph.2025.05.003
文章导航
收藏切换

特应性皮炎(atopic dermatitis,AD)是一种常见的慢性炎症性皮肤病,严重影响患者生活质量。传统治疗如局部类固醇及免疫抑制剂在部分患者中疗效有限,且伴有不良反应。近年来,生物制剂通过靶向关键炎症因子,为中重度AD患者提供全新的治疗选择。度普利尤单抗作为首个获批的生物制剂,可改善患者的皮肤症状及瘙痒感,随后曲罗芦单抗、来瑞组单抗及奈莫利珠单抗等药物进一步丰富了靶向治疗的选择。生物制剂在提升中重度AD患者的治疗效果方面展现出良好的应用前景,并有望通过个性化医学、优化给药策略及成本控制进一步提升疗效和可负担性。该文就主要生物制剂的作用靶点、作用机制及临床研究进展作综述,以期为AD患者的临床治疗提供参考。

特应性皮炎  /  生物制剂  /  生物学功能

Atopic dermatitis (AD) is a common chronic inflammatory skin disease that seriously affects the quality of life of patients. Traditional treatments such as topical steroids and immunosuppressants have limited efficacy in some patients and are accompanied by adverse reactions. In recent years, biologics have provided new treatment options for patients with moderate to severe AD by targeting key inflammatory factors. Dupilumab, as the first approved biologic, significantly improved patients' skin symptoms and pruritus. Subsequently, drugs such as tralokinumab, lebrikizumab, and nemolizumab further expanded the options for targeted therapy. Biologics have shown promising prospects in improving the treatment outcomes of patients with moderate to severe AD, and are expected to further improve efficacy and affordability through personalized medicine, optimized dosing strategies, and cost control. This article reviewed the targets, mechanisms of action, and clinical research progress of major biological agents, in order to provide reference for the clinical treatment of AD patients.

atopic dermatitis  /  biological agents  /  biological function
张卓, 秦成, 王芳, 杨雪松, 叶建州. 生物制剂在特应性皮炎治疗中的研究进展. 世界临床药物, 2025 , 46 (5) : 439 -445 . DOI: 10.13683/j.wph.2025.05.003
Zhuo ZHANG, Cheng QIN, Fang WANG, Xuesong YANG, Jianzhou YE. Research progress of biologics in the treatment of atopic dermatitis[J]. World Clinical Drug, 2025 , 46 (5) : 439 -445 . DOI: 10.13683/j.wph.2025.05.003
  • 国家自然科学基金项目(82260940)
参考文献 引证文献
排序方式:
[1]
FRAZIER W, BHARDWAJ N. Atopic dermatitis: diagnosis and treatment[J]. Am Fam Physician, 2020, 101(10): 590-598.
[2]
SROKA-TOMASZEWSKA J, TRZECIAK M. Molecular mechanisms of atopic dermatitis pathogenesis[J]. Int J Mol Sci, 2021, 22(8): 4130.
[3]
SCHULER C F, BILLI AC, MAVERAKIS E, et al. Novel insights into atopic dermatitis[J]. J Allergy Clin Immunol,2023, 151(5): 1145-1154.
[4]
GATMAITAN JG, LEE JH. Challenges and future trends in atopic dermatitis[J]. Int J Mol Sci, 2023, 24(14): 11380.
[5]
EICHENFIELD LF, STRIPLING S, FUNG S, et al. Recent developments and advances in atopic dermatitis: A focus on epidemiology, pathophysiology, and treatment in the pediatric setting[J]. Pediatric Drugs, 2022, 24(4): 293-305.
[6]
BOCQUEL S, SORIA A, RAISON-PEYRON N, et al.Impact of dupilumab on patch test results and allergic contact dermatitis: a prospective multicenter study[J]. J Am Acad Dermatol, 2024, 90(3): 512-520.
[7]
BANGERT C, RINDLER K, KRAUSGRUBER T, et al.Persistence of mature dendritic cells, Th2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Rα blockade[J]. Sci Immunol, 2021, 6(55): eabe2749.
[8]
TOMINAGA M, TAKAMORI K. Peripheral itch sensitization in atopic dermatitis[J]. Allergol Int, 2022, 71(3): 265-277.
[9]
FURUE M, ULZII D, VU YH, et al. Pathogenesis of atopic dermatitis: current paradigm[J]. Iran J Immunol, 2019,16(2): 97-107.
[10]
RENERT-YUVAL Y, THYSSEN JP, BISSONNETTE R, et al. Biomarkers in atopic dermatitis - a review on behalf of the International Eczema Council[J]. J Allergy Clin Immunol,2021, 147(4): 1174-1190.
[11]
LUGOVIC-MIHIC L, MESTROVIC-STEFEKOV J,POTOCNJAK I, et al. Atopic dermatitis: disease features,therapeutic options, and a multidisciplinary approach[J].Life(Basel), 2023, 13(6): 1419.
[12]
YANG G, SEOK JK, KANG HC, et al. Skin barrier abnormalities and immune dysfunction in atopic dermatitis[J]. Int J Mol Sci, 2020, 21(8): 2867.
[13]
BECK LA, CORK MJ, AMAGAI M, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis[J]. JID Innov, 2022, 2(5): 100131.
[14]
KIM J, KIM BE, LEUNG DYM. Pathophysiology of atopic dermatitis: clinical implications[J]. Allergy Asthma Proc,2019, 40(2): 84-92.
[15]
KIM Y, LIM K. Skin barrier dysfunction and filaggrin[J].Arch Pharm Res, 2021, 44(1): 36-48.
[16]
RENERT-YUVAL Y, GUTTMAN-YASSKY E. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines[J]. Ann Allergy Asthma Immunol, 2020, 124(1):28-35.
[17]
BRIDGEWOOD C, NEWTON D, BRAGAZZI N, et al.Unexpected connections of the IL-23/IL-17 and IL-4/IL-13 cytokine axes in inflammatory arthritis and enthesitis[J].Semin Immunol, 2021, 58: 101520.
[18]
BRIDGEWOOD C, SHARIF K, FREESTON J, et al.Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy[J]. Rheumatology(Oxford), 2021, 60(5):2461-2466.
[19]
SCIBIOREK M, MTHEMBU N, MANGALI S, et al. IL-4Rα signalling in B cells and T cells play differential roles in acute and chronic atopic dermatitis[J]. Sci Rep, 2023, 13(1): 144.
[20]
JOHNSON MC, BOWERS NL, STROWD LC. Concurrent atopic dermatitis and psoriasis vulgaris: implications for targeted biologic therapy[J]. Cutis, 2022, 109(2): 110-112.
[21]
DUBIN C, DEL DUCA E, GUTTMAN-YASSKY E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis[J]. Expert Rev Clin Immunol, 2021, 17(8): 835-852.
[22]
HASHIMOTO T, YOKOZEKI H, KARASUYAMA H, et al.IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin[J]. J Allergy Clin Immunol, 2023, 151(3): 737-746.
[23]
KEAM SJ. Nemolizumab: first approval[J]. Drugs, 2022,82(10): 1143-1150.
[24]
SERRA-BALDRICH E, SANTAMARIA-BABI L F,FRANCISCO SILVESTRE J. Nemolizumab: An innovative biologic treatment to control interleukin 31, a key mediator in atopic dermatitis and prurigo nodularis[J]. Actas Dermosifiliogr , 2022, 113(7): 674-684.
[25]
FURUE M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis[J]. Int J Mol Sci, 2020,21(15): 5382.
[26]
BOROWCZYK J, SHUTOVA M, BREMBILLA NC,et al. IL-25(IL-17E) in epithelial immunology and pathophysiology[J]. J Allergy Clin Immunol, 2021, 148(1):40-52.
[27]
LIU TM, LI S, YING SN, et al. The IL-23/IL-17 pathway in inflammatory skin diseases: from bench to bedside[J]. Front Immunol, 2020, 11: 594735.
[28]
REICH K, THYSSEN JP, BLAUVELT A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised,double-blind, multicentre phase 3 trial[J]. Lancet, 2022,400(10348): 273-282.
[29]
GUTTMAN-YASSKY E, BISSONNETTE R, UNGAR B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis[J].J Allergy Clin Immunol, 2019, 143(1): 155-172.
[30]
SILVERBERG JI, YOSIPOVITCH G, SIMPSON EL,et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS[J]. J Am Acad Dermatol, 2020, 82(6): 1328-1336.
[31]
BLAUVELT A, DE BRUIN-WELLER M, GOODERHAM M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids(LIBERTY AD CHRONOS): a 1-year,randomised, double-blinded, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10086): 2287-2303.
[32]
KOSKERIDIS F, EVANGELOU E, NTZANI EE, et al.Treatment with dupilumab in patients with atopic dermatitis:systematic review and meta-analysis[J]. J Cutan Med Surg,2022, 26(6): 613-621.
[33]
BLAUVELT A, GUTTMAN-YASSKY E, PALLER AS, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: Results through week 52 from a phase Ⅲ open-label extension trial(LIBERTY AD PED-OLE)[J]. Am J Clin Dermatol, 2022, 23(3): 365-383.
[34]
MULLER S, MAINTZ L, BIEBER T. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs[J]. Allergy, 2024, 79(6): 1501-1515.
[35]
WOLLENBERG A, BLAUVELT A, GUTTMAN-YASSKY E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized,double-blind, multicentre, placebo-controlled phase Ⅲtrials(ECZTRA 1 and ECZTRA 2)[J]. Br J Dermatol, 2021,184(3): 437-449.
[36]
PEREYRA-RODRIGUEZ JJ, HERRANZ P, RUIZ-VILLAVERDE R, et al. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results[J]. Clin Exp Dermatol, 2023,48(9): 991-997.
[37]
DE GREEF A, BAECK M. Tralokinumab-induced injection-site reactions[J]. Contact Dermatitis, 2024, 91(6): 521-522.
[38]
SILVERBERG JI, THYSSEN JP, FAHRBACH K, et al.Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis[J]. J Eur Acad Dermatol Venereol, 2021, 35(9): 1797-1810.
[39]
OKRAGLY AJ, RYUZOJI A, WULUR I, et al. Binding,neutralization and internalization of the interleukin-13 antibody, lebrikizumab[J]. Dermatol Ther, 2023, 13(7):1535-1547.
[40]
SIMPSON EL, DE BRUIN-WELLER M, HONG HC, et al.Lebrikizumab provides rapid clinical responses across all eczema area and severity index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis[J]. Dermatol Ther(Heidelb), 2024, 14(5): 1145-1160.
[41]
BUTALA S, CASTELO-SOCCIO L, SESHADRI R, et al.Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations[J]. J Allergy Clin Immunol Pract, 2023, 11(5): 1361-1373.
[42]
RATCHATASWAN T, BANZON TM, THYSSEN JP, et al.Biologics for treatment of atopic dermatitis: current status and future prospect[J]. J Allergy Clin Immunol Pract, 2021,9(3): 1053-1065.
[43]
YANG N, CHEN ZY, ZHANG XL, et al. Novel targeted biological agents for the treatment of atopic dermatitis[J].Bio Drugs, 2021, 35(4): 401-415.
[44]
LABIB A, VANDER DOES A, YOSIPOVITCH G.Nemolizumab for atopic dermatitis[J]. Drugs Today(Barc),2022, 58(4): 159-173.
[45]
KWATRA SG, YOSIPOVITCH G, LEGAT FJ, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis[J]. N Engl J Med, 2023, 389(17): 1579-1589.
[46]
KABASHIMA K, MATSUMURA T, KOMAZAKI H, et al.Trial of nemolizumab and topical agents for atopic dermatitis with pruritus[J]. N Engl J Med, 2020, 383(2): 141-150.
[47]
NILFOROUSHZADEH MA, HEIDARI N, GHANE Y, et al. A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis[J]. Inflammopharmacology,2024, 32(2): 991-1003.
[48]
FURUE M, FURUE M. Interleukin-31 and pruritic skin[J]. J Clin Med, 2021, 10(9): 1906.
[49]
FUKUMOTO T, TANAKA R, TANAKA R, et al. Primary localized cutaneous amyloidosis associated with atopic dermatitis treated successfully with nemolizumab[J]. J Eur Acad Dermatol Venereol, 2024, 38(11): e989-e992.
2025年第46卷第5期
57
12
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2025.05.003
  • 接收时间:2024-11-17
  • 首发时间:2026-11-09
  • 出版时间:2025-05-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-11-17
基金
国家自然科学基金项目(82260940)
作者信息
    1.云南中医药大学第一临床医学院,云南 昆明 650500
    2.云南中医药大学第一附属医院皮肤科,云南 昆明 650500

通讯作者:

叶建州,主任医师,研究方向:特应性皮炎的防治。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.05.003
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏